240 related articles for article (PubMed ID: 36483036)
1. Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective.
Ma X; Ding Y; Li W; Li Q; Yang H
Front Oncol; 2022; 12():1061065. PubMed ID: 36483036
[TBL] [Abstract][Full Text] [Related]
2. Role of Combined
Kaewput C; Vinjamuri S
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204371
[TBL] [Abstract][Full Text] [Related]
3. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.
Pobłocki J; Jasińska A; Syrenicz A; Andrysiak-Mamos E; Szczuko M
Nutrients; 2020 May; 12(5):. PubMed ID: 32429294
[TBL] [Abstract][Full Text] [Related]
4. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
5. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
6. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Kaliszewski K; Ludwig M; Greniuk M; Mikuła A; Zagórski K; Rudnicki J
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454934
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
Waseem N; Aparici CM; Kunz PL
J Nucl Med; 2019 Jul; 60(7):882-891. PubMed ID: 30850504
[TBL] [Abstract][Full Text] [Related]
10. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
11. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
12. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
Takayanagi D; Cho H; Machida E; Kawamura A; Takashima A; Wada S; Tsunoda T; Kohno T; Shiraishi K
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267427
[TBL] [Abstract][Full Text] [Related]
13. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
14. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
15. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.
Danti G; Flammia F; Matteuzzi B; Cozzi D; Berti V; Grazzini G; Pradella S; Recchia L; Brunese L; Miele V
Radiol Med; 2021 Dec; 126(12):1497-1507. PubMed ID: 34427861
[TBL] [Abstract][Full Text] [Related]
17. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy.
Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.
Pellegrino F; Granata V; Fusco R; Grassi F; Tafuto S; Perrucci L; Tralli G; Scaglione M
Tomography; 2023 Jan; 9(1):217-246. PubMed ID: 36828370
[TBL] [Abstract][Full Text] [Related]
20. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
